New scoring system for predicting relapse after lamivudine-induced hepatitis B e-antigen loss in chronic hepatitis B patients

Hepatology Research

Volumn 39, Issue 11, 2009, Pages 1064-1071

  Song, Byung Cheol ^a   Cui, Xiu Ji ^a   Cho, Yoo Kyung ^a   Choi, Eun Kwang ^a   Hyun, Soyoung ^a   Song, Hyun Joo ^a   Kim, Heung Up ^a  

^a Jeju National University School of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; HBeAg loss; Lamivudine; Relapse

Indexed keywords

ADEFOVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; LIVER CIRRHOSIS; MALE; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM;

EID: 73649123193     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00560.x     Document Type: Article

References (34)

1. Dienstag J.L. Hepatitis b virus infection. N Engl J Med 2008; 2 (359): 1486-500.
2. Lok AS, McMahon B.J. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
3. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 7 (351): 1521-31.
4. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 30 (334): 1422-7.
5. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 21 (341): 1256-63.
6. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 9 (339): 61-8.
7. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 15 (36): 687-96.
8. Dienstag JL, Cianciara J, Karayalcin S et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37: 748-55.
9. Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30: 1082-7.
10. Lee CM, Ong GY, Lu SN et al. Durability of lamivudineinduced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 2002; 37: 669- 74.
11. Song BC, Suh DJ, Lee HC, Chung YH, Lee Y.S. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-6.
12. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw Y.F. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38: 1267-73.
13. Byun KS, Kwon OS, Kim JH et al. Factors related to posttreatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. J Gastroenterol Hepatol 2005; 20: 1838-42.
14. Lee HC, Suh DJ, Ryu SH et al. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut 2003; 52: 1779-83.
15. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim J.H. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002; 9: 208-12.
16. Bruix J, Castells A, Bosch J et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: 1018-22.
17. Di Lelio A, Cestari C, Lomazzi A, Beretta L. Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology 1989; 172: 389-92.
18. Chan HL, Hui AY, Wong ML et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-8.
19. Chu CM, Liaw Y.F. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005; 43: 411-17.
20. Chu CM, Liaw Y.F. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007; 133: 1458-65.
21. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen H.L. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101: 297-303.
22. Kao JH, Chen PJ, Lai MY, Chen D.S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-9.
23. Kao JH, Wu NH, Chen PJ, Lai MY, Chen D.S. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998-1002.
24. Wai CT, Chu CJ, Hussain M, Lok A.S. HBV genotype B is associated with better response to interferon therapy in HBeAg(+)chronic hepatitis than genotype C. Hepatology 2002; 36: 1425-30.
25. Yuen MF, Sablon E, Yuan HJ et al. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 2003; 37: 562-7.
26. Yuen MF, Tanaka Y, Lai C.L. Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy. Intervirology 2003; 46: 373-6.
27. Lee SH, Lee SH, Han SH et al. Distribution of HBV genotypes in patients with chronic HBV infection in Korea. Korean J Hepatol 2001; 7: 373-80.
28. Song BC, Cui XJ, Kim H. Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection. Intervirology 2005; 48: 133-7.
29. Kim H, Jee YM, Song BC et al. Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. Intervirology 2007; 50: 52-7.
30. Miyakawa Y, Mizokami M. Classifying hepatitis B virus genotypes. Intervirology 2003; 46: 329-38.
31. Song BC, Ghany M, Lee HC, Chung YH, Lee Y.S. Which patients with chronic hepatitis B are more likely to relapse after interferon alpha-induced hepatitis B e antigen loss in Korea? J Clin Gastroenterol 2004; 38: 124-9.
32. Ryu SH, Chung YH, Choi MH et al. Long-term additional lamivudine therapy enhances durability of lamivudineinduced HBeAg loss: a prospective study. J Hepatol 2003; 39: 614-19.
33. Davis GL, Hoofnagle JH, Waggoner J.G. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology 1984; 86: 230-5.
34. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis Annu Rev Immunol 1995; 13: 29-60.